Ono Pharmaceutical has been granted a patent for compounds that inhibit autophagy, specifically for their application in treating cancers. The patent outlines a method for administering these compounds to patients requiring cancer treatment. GlobalData’s report on Ono Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ono Pharmaceutical, Peptide pharmacophores was a key innovation area identified from patents. Ono Pharmaceutical's grant share as of July 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
The patent US12071432B2 outlines methods for treating various types of cancer by administering a therapeutically effective amount of a compound represented by a specific formula. The claims detail the use of MEK inhibitors, specifically naming selumetinib and cobimetinib, along with their pharmaceutically acceptable salts. The methods are applicable to a wide range of cancers, including but not limited to gastrointestinal stromal tumors, esophageal cancer, gastric cancer, melanomas, gliomas, glioblastomas, ovarian cancer, and several others. The claims also specify various structural modifications of the compounds, including specific groups and substituents that can be utilized in the formulations.
Further claims elaborate on the structural components of the compounds, detailing specific groups such as halogens, alkyls, and cycloalkyls, as well as the potential for various stereoisomers and tautomers. The patent emphasizes the versatility of the compounds in targeting multiple cancer types, indicating a broad therapeutic potential. The detailed chemical structures and variations provided in the claims suggest a comprehensive approach to developing effective cancer treatments, potentially enhancing the efficacy and specificity of the therapeutic agents involved.
To know more about GlobalData’s detailed insights on Ono Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
